World CNS Series

Next month,?Mathias Schmidt, Executive Advisor to the President, Chairman, &?CEO of?JCR Pharmaceuticals, will present at the 6th Annual CNS Drug Delivery Summit hosted by the?World CNS Series, which takes places from Dec. 3-5 in Boston, MA. Learn more about the summit here:?https://bit.ly/3YlObrh.? ? In addition, in an interview prior to the conference, Mathias spoke about how drug delivery has evolved, and how JCR’s approach to targeting the central nervous system (#CNS) is advancing the field.?For more on Mathias’s thoughts, read the full interview here:?https://bit.ly/3zo7CY0.? ? See you at the summit if you’re planning to attend! ? #RareDisease #BloodBrainBarrier #Neurodegeneration #CNS #LysosomalStorageDisorders #JCRPharma

Acumen Pharmaceuticals, Inc., Johnson & Johnson, Annovis Bio, Inc., AbbVie, Lexeo Therapeutics, and others are set to showcase cutting-edge advancements in ?????? ?????????????? ?????? ???????????????????? transforming the neurodegenerative treatment landscape. Join 150+ industry pioneers at the ???????? ??????????????????’?? & ??????????????????’?? ???????? ?????????????????????? ???????????? to benchmark progress and discuss innovative programs targeting tau, 15-Lipoxygenase, mitochondrial dysfunction, TDP-43 and more. Early bird registration expires this Friday: https://ter.li/vgrpr9 #amyloid #tau #alphasynuclein #neuroinflammation #mitochondria #TDP43

Join us at the 13th Alzheimer’s & Parkinson’s Drug Development Summit which unites 150+ Alzheimer’s and Parkinson’s experts, with pioneering insights as they address their most pressing challenges in a collaborative atmosphere to spearhead the next wave of more truly transformative neurodegenerative therapeutics. MJFF senior scientific portfolio manager Luis Miguel Oliveira will be joining the speaker faculty to showcase advancements in α-Synuclein seed amplification assays and discuss novel fluid markers beyond protein aggregation. MJFF Patient Council member Peter DiBiaso will represent the patient voice among industry discussions on what’s to come from the next wave of disease-modifying PD therapeutics. Learn more: https://ter.li/xv05q0

Leading biotech and pharma companies like Roche, Johnson & Johnson, Novartis, Biogen, Eisai US, Ionis Pharmaceuticals, Inc., and 50+ others will unite to push the boundaries of CNS drug delivery next month. Teams from Eli Lilly and Company, Neurocrine Biosciences, Aliada Therapeutics, Novo Nordisk, and Alnylam Pharmaceuticals have recently secured their spots, meaning we’re almost at capacity, secure your teams here: https://ter.li/l2u1pf What to expect: ?? 25+ data-driven case study presentations covering topics like: - Screening for brain-penetrant antibodies - Advancing microfluidic BBB models - Overcoming drug-CSF compatibility & more ?? 10+ hours of collaborative discussions on key challenges in CNS delivery, including: - Systemic antisense and LNP delivery - CED, FUS invasiveness, and novel BBB receptor utilization ?? Exclusive scientific poster session where you can present your latest research to 150+ industry leaders. (Poster submissions close next week!) ?? Agenda preview: View all the incredible sessions and opportunities in our industry-focused agenda: https://ter.li/01b9p0 ?? Limited spots remaining; secure your place: https://ter.li/l2u1pf

Only ?? ?????????? ???? ???? until 150+ biotech and pharma leaders unite at industry’s dedicated ?????? ?????? ???????? ???????????????? ????????????, to share breakthrough progress in the delivery of antibodies, ASOs, LNPs, AAVs and more, and accelerate the development of more ??????????-?????????????????? therapeutics. View the official agenda and 35+ speaker faculty here https://ter.li/i5ef7c and secure your place before midnight tomorrow to make the most of ?????????? ???????????????????????? ??????????????! Proud to partner with Renishaw Neurological products Renishaw Bionaut Labs Neurochase Realeve LLC Aptar Pharma

With a game-changing era of disease-modifying drug approvals, transformed diagnostic capabilities, and pipelines bursting with novel approaches targeting the likes of tau, LRRK2 and NLRP3, I’m thrilled to announce the release of the ???????? ??????????????????’?? & ??????????????????’?? ???????? ?????????????????????? ???????????? 2025 agenda! Be the first to view the brand-new program: https://ter.li/r3plge Join our largest gathering yet, with pioneering insights from ??????????, ????????????, ?????? ??????????, ??&??, ????????????, ??????????, ????????????, ????????????????, ????????????????, ????????, ??-???????? & many more to: ???Translate Novel Targets Beyond Aβ & Advance the Reality of Blood-Based Biomarkers for Commercially Successful AD Therapeutics ???Enhance α-Synuclein Detection, Improve Biological Understanding & Innovate a New Era of Disease-Modifying PD Therapies

?? EARLY BIRD ENDS THIS FRIDAY! ?? Unlock the Future of Protein Degradation at the 2nd Protein Degradation for CNS Summit. Why attend? ?? Connect with industry leaders and forge lasting?relationships to share knowledge and form collaborations ?? Stay ahead of the curve with the latest advancements in protein degradation for the treatment of CNS diseases ?? Contribute to ground breaking discussions and collaborative efforts at the round table and panel discussions Join 80+ experts from the leading biotechnology and pharmaceutical companies in?the industry to reshape the future of CNS disease treatment. Find out more here: https://ter.li/e4cqv3 #proteindegradation #CNS #neuroscience #TPD #neurodegenerative

Will you be joining Eli Lilly and Company, Eisai Co., Ltd., JCR Pharmaceuticals, Ionis Pharmaceuticals, Inc., Novartis, Alnylam Pharmaceuticals, Acumen Pharmaceuticals, Inc., Neurocrine Biosciences, Alector, Takeda and more at this year’s ?????? ?????? ???????? ???????????????? ????????????? Take a sneak peek at the attendee list so far! Join ??????+ preclinical and translational neuroscientists, protein engineers, conjugation chemists, drug delivery and device experts, DMPK scientists, and more at the only ????????????????-??????????????, ??????????-???????????????????? meeting. Engage in forward-thinking discussions to advance???????????????????????? ???????????????? ?????? ?????????? ???????????????? ?????????????? for safer, more targeted delivery to ???????????????? ?????????? ??????????????. Hear from ????+ ???????????? ???????????????? including Christopher Kadamus Krista Spiller, Niels Janssen, Mathias Schmidt, Iosif (Sifis) Pediaditakis, Smrithi Padmakumar, Ph.D., Yuan Yuan, Sho Sato and Raymond Tong. Check out the full speaker faculty: https://ter.li/zwt8i9 #worldcns #cnsdrugdelivery #expertspeakers

JUST LAUNCHED? Building on last years success, the Protein Degradation for CNS?Summit?returns to Boston. This years summit includes: ?? Sessions?designed to share research and data?with an aim of?progressing?the field of?protein degradation for CNS diseases? ?? 4?workshop sessions to?gain a?deeper?understanding of neurodegenerative diseases/protein degradation ?? 2 round table discussions for the sharing of diverse perspectives ?? Networking sessions to?facilitate?the sharing of knowledge and?fostering collaborations? ?? 15+ expert speakers including: Beth J Hoffman, Lili Zhang, Patrick Wen, Simon Glerup, Magnus Walter, Mikolaj Slabicki, Marianthi Papakosta, Ph.D., Pranam Chatterjee Be one of the first to view the 2025 agenda here: https://ter.li/p27p94